Why Is TARSUS PHARMACEUTICA (TARS) Stock Up Today?

TARS stock is up 11.76% today, closing at $82.76, driven by the company's announcement that management will participate in investor conferences and recent analyst activity. The stock has been in a strong upward trend, having risen 8.5% over the past eight sessions and reaching a new 52-week high on September 2, 2026. The move follows a recent acquisition agreement and a price target increase from Oppenheimer.

What Happened

Tarsus Pharmaceuticals announced that its management team will attend the upcoming Wells Fargo investor conference, signaling increased engagement with the investment community. The company also recently agreed to acquire Alkeus Pharmaceuticals for $450 million upfront in cash and stock, with up to $350 million in additional milestones. Alkeus is developing gildeuretinol, an investigational therapy for Stargardt disease, which has received orphan drug designation in Japan. Oppenheimer analysts have maintained an Outperform rating on Tarsus and raised their price target to $100. Tarsus also reported Q2 results that beat revenue estimates but missed earnings expectations.

What The Data Shows

Tarsus has a market cap of $3.3 billion and is currently unprofitable with a trailing twelve-month (TTM) EPS of -1.08. Despite this, the company has seen a 105.2% year-over-year increase in revenue. The stock has traded between $48.20 and $85.25 over the past 52 weeks. Insiders have sold a total of $2.5 million worth of shares in the last 90 days, with the most recent filing on June 22, 2026. The stock has a beta of 0.51, indicating it is less volatile than the broader market.

What To Watch

Tarsus does not have an upcoming earnings date in the provided data. Investors should monitor the company’s participation in the investor conferences and the progress of the Alkeus acquisition. Coverage breadth and analyst commentary will also be key to watch in the coming weeks.